Literature DB >> 15699417

Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants.

Leonardo J M Carvalho1, Francisco A Alves, Cesare Bianco, Salma G Oliveira, Graziela M Zanini, Soe Soe, Pierre Druilhe, Michael Theisen, José A P C Muniz, Cláudio T Daniel-Ribeiro.   

Abstract

The immunogenicity and efficacy of a hybrid recombinant protein derived from the N-terminal end of the glutamate-rich protein (GLURP) and the C-terminal portion of the merozoite surface protein 3 (MSP3) of Plasmodium falciparum was evaluated in Saimiri sciureus monkeys. The GLURP/MSP3 hybrid protein, expressed in Lactococcus lactis, was administered in association with alum, Montanide ISA720, or complete or incomplete Freund adjuvant (CFA/IFA) in groups of five animals each. The three formulations were shown to be immunogenic, but the one with alum was shown to be weak compared to the other two, particularly CFA/IFA, which provided very high antibody titers (enzyme-linked immunosorbent assay titers of >3,000,000 and immunofluorescence antibody test titers of 6,400). After a challenge infection with P. falciparum FUP strain, all five monkeys from the GLURP/MSP3-alum group showed a rapid increase in parasitemia, reaching 10% and were treated early. The two monkeys with the highest antibody titers in group GLURP/MSP3-Montanide ISA720 had a delay in the course of parasitemia and were treated late due to a low hematocrit. In the GLURP/MSP3-CFA/IFA group, parasitemia remained below this threshold in four of the five animals and, after it reached a peak, parasitemia started to decrease and monkeys were treated late. When all animals were grouped according to the outcome, a statistically significant association between high antibody titers and partial protection was observed. The challenge infection boosted the antibody titers, and the importance of this event for vaccine efficacy in areas where this parasite is endemic is discussed. In conclusion, these data suggest that GLURP and MSP3 can induce protection against malaria infection if antibodies are induced at properly high titers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699417      PMCID: PMC549299          DOI: 10.1128/CDLI.12.2.242-248.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  15 in total

1.  Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.

Authors:  Hajime Hisaeda; Allan Saul; Joshua J Reece; Michael C Kennedy; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  J Infect Dis       Date:  2002-02-14       Impact factor: 5.226

2.  Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing.

Authors:  M Theisen; S Soe; S G Jessing; L M Okkels; S Danielsen; C Oeuvray; P Druilhe; S Jepsen
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

3.  Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle.

Authors:  M B Borre; M Dziegiel; B Høgh; E Petersen; K Rieneck; E Riley; J F Meis; M Aikawa; K Nakamura; M Harada
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

4.  The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro.

Authors:  M Theisen; S Soe; C Oeuvray; A W Thomas; J Vuust; S Danielsen; S Jepsen; P Druilhe
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

5.  Role of non-human primates in malaria vaccine development: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

6.  Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity.

Authors:  M Theisen; D Dodoo; A Toure-Balde; S Soe; G Corradin; K K Koram; J A Kurtzhals; L Hviid; T Theander; B Akanmori; M Ndiaye; P Druilhe
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 7.  The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden.

Authors:  J G Breman
Journal:  Am J Trop Med Hyg       Date:  2001 Jan-Feb       Impact factor: 2.345

8.  Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.

Authors:  S Kumar; W Collins; A Egan; A Yadava; O Garraud; M J Blackman; J A Guevara Patino; C Diggs; D C Kaslow
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

9.  Variant- and strain-specific immunity in Saimiri infected with Plasmodium falciparum.

Authors:  T Fandeur; W Chalvet
Journal:  Am J Trop Med Hyg       Date:  1998-02       Impact factor: 2.345

Review 10.  Malaria vaccine: candidate antigens, mechanisms, constraints and prospects.

Authors:  L J M Carvalho; C T Daniel-Ribeiro; H Goto
Journal:  Scand J Immunol       Date:  2002-10       Impact factor: 3.487

View more
  21 in total

1.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 2.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

3.  Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.

Authors:  Jean Claude Dejon-Agobe; Ulysse Ateba-Ngoa; Albert Lalremruata; Andreas Homoet; Julie Engelhorn; Odilon Paterne Nouatin; Jean Ronald Edoa; José F Fernandes; Meral Esen; Yoanne Darelle Mouwenda; Eunice M Betouke Ongwe; Marguerite Massinga-Loembe; Stephen L Hoffman; B Kim Lee Sim; Michael Theisen; Peter G Kremsner; Ayôla A Adegnika; Bertrand Lell; Benjamin Mordmüller
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

4.  Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon.

Authors:  Benjamin Mordmüller; Katja Szywon; Benedikt Greutelaers; Meral Esen; Ludovic Mewono; Carolin Treut; Raymund E Mürbeth; Roma Chilengi; Ramadhani Noor; Wen L Kilama; Egeruan Babatunde Imoukhuede; Nathalie Imbault; Odile Leroy; Michael Theisen; Søren Jepsen; Paul Milligan; Rolf Fendel; Peter G Kremsner; Saadou Issifou
Journal:  Vaccine       Date:  2010-08-07       Impact factor: 3.641

5.  GMZ2 Vaccine-Induced Antibody Responses, Naturally Acquired Immunity and the Incidence of Malaria in Burkinabe Children.

Authors:  Sylvester Dassah; Bright Adu; Régis W Tiendrebeogo; Susheel K Singh; Fareed K N Arthur; Sodiomon B Sirima; Michael Theisen
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

6.  A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.

Authors:  Sabine Bélard; Saadou Issifou; Aurore B Hounkpatin; Frieder Schaumburg; Ulysse Ateba Ngoa; Meral Esen; Rolf Fendel; Pablo Martinez de Salazar; Raymund E Mürbeth; Paul Milligan; Nathalie Imbault; Egeruan Babatunde Imoukhuede; Michael Theisen; Søren Jepsen; Ramadhani A Noor; Brenda Okech; Peter G Kremsner; Benjamin Mordmüller
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

7.  Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.

Authors:  Marco Tamborrini; Sabine A Stoffel; Nicole Westerfeld; Mario Amacker; Michael Theisen; Rinaldo Zurbriggen; Gerd Pluschke
Journal:  Malar J       Date:  2011-12-13       Impact factor: 2.979

8.  Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.

Authors:  Marco Tamborrini; Markus S Mueller; Sabine A Stoffel; Nicole Westerfeld; Denise Vogel; Francesca Boato; Rinaldo Zurbriggen; John A Robinson; Gerd Pluschke
Journal:  Malar J       Date:  2009-12-30       Impact factor: 2.979

9.  Igh locus structure and evolution in Platyrrhines: new insights from a genomic perspective.

Authors:  Diego Garzón-Ospina; Sindy P Buitrago
Journal:  Immunogenetics       Date:  2019-12-14       Impact factor: 2.846

10.  Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.

Authors:  Hassen Mamo; Meral Esen; Anthony Ajua; Michael Theisen; Benjamin Mordmüller; Beyene Petros
Journal:  Malar J       Date:  2013-02-05       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.